- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05538897
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the toxicity of ipatasertib in combination with megestrol acetate in women with metastatic grade 1-2 endometrioid endometrial cancer and establish the recommended phase II dose. (Phase I) II. Compare the progression free survival of the combination of ipatasertib with megestrol acetate to megestrol acetate alone among women with metastatic grade 1-2 endometrioid adenocarcinoma of the endometrium. (Phase II) III. Compare the toxicity of the combination of ipatasertib with megestrol acetate to megestrol acetate alone. (Phase II)
SECONDARY OBJECTIVES:
I. Compare objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the two arms.
II. Examine the pharmacokinetics of ipatasertib + megestrol acetate to assess potential drug-drug interactions.
III. Assess the association between biomarkers and response to therapy.
EXPLORATORY OBJECTIVE:
I. Explore whether pS6/total S6 and pPRAS40/total PRAS40 expression is impacted by the use of ipatasertib and megestrol acetate.
OUTLINE: This is a phase Ib, dose de-escalation study of ipatasertib followed by a phase II study.
PHASE Ib: Patients receive megestrol acetate orally (PO) once daily (QD) on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a computed tomography (CT) or magnetic resonance imaging (MRI) during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive megestrol acetate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
ARM II: Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI during screening, on study, and during follow-up. Patients also undergo collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up at 30 days for the phase I study. Patients are followed up every 3 months for 2 years, then every 6 months for 3 years for the phase II study.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Recruiting
- Banner University Medical Center - Tucson
-
Principal Investigator:
- Setsuko K. Chambers
-
Contact:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
Tucson, Arizona, United States, 85719
- Recruiting
- University of Arizona Cancer Center-North Campus
-
Principal Investigator:
- Setsuko K. Chambers
-
Contact:
- Site Public Contact
- Email: UACC-IIT@uacc.arizona.edu
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- UCHealth University of Colorado Hospital
-
Contact:
- Site Public Contact
- Phone Number: 720-848-0650
-
Principal Investigator:
- Bradley R. Corr
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida Health Science Center - Gainesville
-
Contact:
- Site Public Contact
- Phone Number: 352-273-8010
- Email: cancer-center@ufl.edu
-
Principal Investigator:
- Merry J. Markham
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Augusta University Medical Center
-
Principal Investigator:
- Sharad A. Ghamande
-
Contact:
- Site Public Contact
- Phone Number: 706-721-2388
- Email: ga_cares@augusta.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa/Holden Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-237-1225
-
Principal Investigator:
- David P. Bender
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota/Masonic Cancer Center
-
Principal Investigator:
- Deanna G. Teoh
-
Contact:
- Site Public Contact
- Phone Number: 612-624-2620
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Recruiting
- Mercy Hospital Saint Louis
-
Principal Investigator:
- Jay W. Carlson
-
Contact:
- Site Public Contact
- Phone Number: 314-251-7066
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Recruiting
- University of New Mexico Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 505-925-0348
- Email: HSC-ClinicalTrialInfo@salud.unm.edu
-
Principal Investigator:
- Carolyn Y. Muller
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Principal Investigator:
- Olivia D. Lara
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Recruiting
- UHHS-Chagrin Highlands Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Amy Armstrong
-
Centerville, Ohio, United States, 45459
- Recruiting
- Miami Valley Hospital South
-
Contact:
- Site Public Contact
- Phone Number: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Principal Investigator:
- Michael S. Guy
-
Chardon, Ohio, United States, 44024
- Recruiting
- Geauga Hospital
-
Contact:
- Site Public Contact
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Amy Armstrong
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Contact:
- Site Public Contact
- Phone Number: 866-223-8100
- Email: TaussigResearch@ccf.org
-
Principal Investigator:
- Peter G. Rose
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Case Western Reserve University
-
Contact:
- Site Public Contact
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Amy Armstrong
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Principal Investigator:
- David M. O'Malley
-
Contact:
- Site Public Contact
- Phone Number: 800-293-5066
- Email: Jamesline@osumc.edu
-
Mentor, Ohio, United States, 44060
- Recruiting
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Contact:
- Site Public Contact
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Amy Armstrong
-
Westlake, Ohio, United States, 44145
- Recruiting
- UH Seidman Cancer Center at Saint John Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 800-641-2422
- Email: CTUReferral@UHhospitals.org
-
Principal Investigator:
- Amy Armstrong
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Phone Number: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Principal Investigator:
- Debra L. Richardson
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 215-600-9151
- Email: ONCTrialNow@jefferson.edu
-
Principal Investigator:
- Ida Micaily
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Recruiting
- Women and Infants Hospital
-
Contact:
- Site Public Contact
- Phone Number: 401-274-1122
-
Principal Investigator:
- Cara A. Mathews
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Michaela O. Grinsfelder
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Recruiting
- West Virginia University Charleston Division
-
Contact:
- Site Public Contact
- Phone Number: 304-388-9944
-
Principal Investigator:
- Stephen H. Bush
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
Contact:
- Site Public Contact
- Phone Number: 414-805-3666
-
Principal Investigator:
- Elizabeth Hopp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have grade 1 or 2 recurrent or metastatic endometrioid endometrial cancer
- Patients must have measurable disease according to RECIST version (v)1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or MRI. Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI. Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation
- Patients may have received unlimited prior lines of therapy. If patient received prior hormonal therapy (e.g., megestrol acetate, medroxyprogesterone acetate, aromatase inhibitor, tamoxifen, fulvestrant) it must have completed at least 6 months prior to registration
- Age >= 18
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
- Platelets >= 100,000/mcl within 14 days prior to registration
- Absolute neutrophil count (ANC) >= 1,500/mcl within 14 days prior to registration
- Hemoglobin >= 9 g/dL within 14 days prior to registration
- Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2 measured using Cockcroft-Gault equation or the estimated glomerular filtration rate from the Modification of Diet in Renal Disease Study within 14 days prior to registration
Total bilirubin =< 1.5 x the upper limit of normal (ULN) within 14 days prior to registration
- Patients with known Gilbert syndrome who have bilirubin =< 3 x ULN may be enrolled
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN within 14 days prior to registration
- Albumin >= 3 g/dL within 14 days prior to registration
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- The effects of ipatasertib on the developing human fetus are unknown. For this reason and because AKT inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, participants of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during study therapy and for 28 days following the last dose of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
For patients with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) infection:
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
- Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- Patients must be able to swallow and retain oral medications and not have gastrointestinal illnesses that would preclude absorption of megestrol acetate or ipatasertib as judged by the treating physician
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria:
- Patients who have had prior treatment with an AKT inhibitor (Prior treatment with PI3K or mTOR inhibitors is allowed)
Patients who have received treatment with strong CYP3A inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to study registration
- Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with diabetes either requiring insulin therapy or with a baseline fasting glucose > 160 mg/dL and/or high glycosylated hemoglobin A1c (HbA1c) (> 8), suggesting poorly controlled diabetes. Fasting is defined as abstaining from food and drink (with the exception of water) for at least 8 hours
- Patients who require chronic corticosteroid therapy of > 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease
- Patients with grade 2 or greater uncontrolled or untreated hypercholesterolemia (> 300 mg/dL) or hypertriglyceridemia (> 300 mg/dL)
- Patients with a history of known or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
- Patients with a history of or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion (including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction)
- Patients with known clinically significant history of liver disease consistent with Child-Pugh class B or C, including active viral or other hepatitis, current drug or alcohol abuse, or cirrhosis
- Patients with lung disease: Grade 2 or greater pneumonitis, grade 2 or greater interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia) within the past 6 months
- No active infection requiring parenteral antibiotics
- Women who are pregnant or unwilling to discontinue nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase Ib (megestrol acetate, ipatasertib)
Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo a CT or MRI during screening, on study, and during follow-up.
Patients also undergo collection of blood samples throughout the trial.
|
Undergo MRI
Other Names:
Undergo blood sample collection
Other Names:
Given PO
Other Names:
Undergo CT scan
Other Names:
Given PO
Other Names:
|
Active Comparator: Phase II (megestrol acetate)
Arm I: Patients receive megestrol acetate PO QD on days 1-28 of each cycle.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo a CT or MRI during screening, on study, and during follow-up.
Patients also undergo collection of blood samples throughout the trial.
|
Undergo MRI
Other Names:
Undergo blood sample collection
Other Names:
Undergo CT scan
Other Names:
Given PO
Other Names:
|
Experimental: Phase II (megestrol acetate, ipatasertib)
Arm II: Patients receive megestrol acetate PO QD on days 1-28 and ipatasertib PO QD on days 1-21 of each cycle.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients undergo a CT or MRI during screening, on study, and during follow-up.
Patients also undergo collection of blood samples throughout the trial.
|
Undergo MRI
Other Names:
Undergo blood sample collection
Other Names:
Given PO
Other Names:
Undergo CT scan
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs) (Phase Ib)
Time Frame: Up to 5 years
|
To determine frequency and severity of adverse events for all dose combinations of megestrol acetate plus ipatasertib.
Descriptive statistics will be used to summarize AEs.
These analyses will focus on individuals who initiated their assigned treatment and will summarize maximum grade of AEs occurring during treatment classified by Common Toxicity Criteria (CTC) category.
The primary summary of AEs will present counts and percentages, regardless of whether the AE was attributed to any of the study agents.
|
Up to 5 years
|
Maximum tolerated dose for phase II (Phase Ib)
Time Frame: Up to 5 years
|
Descriptive statistics will be used to summarize AEs.
These analyses will focus on individuals who initiated their assigned treatment and will summarize maximum grade of AEs occurring during treatment classified by CTC category.
The primary summary of AEs will present counts and percentages, regardless of whether the AE was attributed to any of the study agents.
|
Up to 5 years
|
Progression free survival (PFS) (Phase II)
Time Frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years
|
Compare PFS of the combination of ipatasertib with megestrol acetate to megestrol acetate alone among women with recurrent/metastatic endometrioid adenocarcinoma of the endometrium.
A product-limit method will be used to estimate the cumulative distribution of PFS duration for each of the study treatments used in this population.
|
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years
|
Incidence of AEs (Phase II)
Time Frame: Up to 5 years
|
Summarize the toxicity/adverse events of the combination of ipatasertib with megestrol acetate and megestrol acetate alone.
Adverse events will be categorized using Common Terminology Criteria for Adverse Events version 5.0.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of ipatasertib + megestrol acetate (Phase Ib)
Time Frame: On cycle 1, day 8
|
Examine the pharmacokinetics of ipatasertib + megestrol acetate to assess potential drug-drug interactions.
This data will be summarized descriptively.
|
On cycle 1, day 8
|
Objective response rate (ORR) (Phase II)
Time Frame: Up to 5 years
|
Response is defined as complete response or partial response (CR+PR) evaluated by Response Evaluation Criteria in Solid Tumors RECIST version 1.1.
A logistic model will be used to estimate the relative odds of responding (CR+PR) to megestrol acetate + ipatasertib relative to megestrol acetate alone after adjusting for prior progesterone therapy.
|
Up to 5 years
|
Biomarkers (Phase II)
Time Frame: Up to 5 years
|
The association between biomarkers and response to therapy will be assessed.
Integrated biomarker endpoints include: PTEN immunohistochemistry, estrogen receptor and progesterone receptor, whole exome sequencing, ribonucleic acid sequencing.
Proportional hazards models will be used to examine the prognostic association of integrated biomarkers with PFS; and interactions between markers and treatment arm will be used to examine the markers' predictive association with PFS.
|
Up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pS6/total S6 and pPRAS40/total PRAS40 expression (Phase II)
Time Frame: Up to 5 years
|
Exploratory objectives include assessing whether pS6/total S6 and pPRAS40/total PRAS40 expression is impacted by the use of ipatasertib and megestrol acetate.
Exploratory biomarker results will be provided to the NRG Oncology Statistical and Data Management Center for analysis.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michaela O Grinsfelder, NRG Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Ovarian Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Recurrence
- Adenocarcinoma
- Endometrial Neoplasms
- Carcinoma, Endometrioid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Megestrol
- Megestrol Acetate
- Ipatasertib
Other Study ID Numbers
- NCI-2022-07505 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180868 (U.S. NIH Grant/Contract)
- NRG-GY028 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Endometrial Endometrioid Adenocarcinoma
-
GOG FoundationNational Cancer Institute (NCI)Active, not recruitingRecurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Korea, Republic of, Canada, Puerto Rico, Japan
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRecurrent Endometrial Adenocarcinoma | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Mixed Cell Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)CompletedEndometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Metastatic Endometrioid AdenocarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Ovarian Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Uterine Corpus Cancer | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Endometrioid AdenocarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation | Endometrioid Stromal SarcomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedFIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 3 Endometrial Endometrioid AdenocarcinomaUnited States
-
Women and Infants Hospital of Rhode IslandUnknownGrade 1 Endometrial Endometrioid Adenocarcinoma | Grade 2 Endometrial Endometrioid Adenocarcinoma | Complex Atypical Endometrial HyperplasiaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditionsUnited States
Clinical Trials on Magnetic Resonance Imaging
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System NeoplasmUnited States